The Korean Pharmaceutical industry, with a history of over 120 years, has made significant contributions to enhancing global health and has emerged as a pivotal driver of economic growth in Korea.

High-quality medicines manufactured by Korean companies are now supplied to more than 210 countries, and Korea is the third country in the world to have successfully developed COVID-19 vaccines and treatments at the same time. Based on its excellent technology, Korea’s pharmaceutical exports have recently exploded, and technology exports are also breaking records every year. In addition, the WHO designated Korea as a 'Global Biomanufacturing Workforce Training Hub' as well.

I would say the future of Korea is brighter. Based on active research and development, Korea now has over 2,000 new drug pipelines, and new drug development using the latest technologies, such as, ADC and CGT, is also actively underway. In addition, Korea is preemptively responding to cutting-edge convergence trends such as artificial intelligence and digital transformation.

Now, the Korean pharmaceutical industry is actively seeking to enter the global market worth more than $1.4 trillion. We are striving to become a global pharmaceutical leader through the promotion of open innovation, and the Korean government is also actively supporting this goal through the 3rd Comprehensive Plan for the Development and Support for Bio-Pharmaceutical Industry. KPBMA also looks forward to your cooperation in improving global health through the development of innovative new drugs.